每经AI快讯，阳普医疗（SZ 300030，收盘价：7.67元）9月29日晚间发布公告称，公司审议通过了《关 于聘任周伟为公司副总经理的议案》。基于公司发展及实际工作需要，经公司控股股东珠海格力金融投 资管理有限公司推荐，代理总经理蒋广成先生提名、董事会提名委员会审核，董事会决定聘任周伟先生 担任公司副总经理。 2024年1至12月份，阳普医疗的营业收入构成为：工业占比99.18%，融资租赁占比0.82%。 截至发稿，阳普医疗市值为24亿元。 每经头条（nbdtoutiao）——农夫大战怡宝，抢到更多蛋糕的却是宗馥莉！农夫绿瓶上市后，怡宝上 演"滑铁卢"：市占率大跌近5个百分点 （记者 张明双） ...

一、审议通过《关于聘任周伟为公司副总经理的议案》 第六届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 阳普医疗科技股份有限公司（以下简称"公司"）第六届董事会第十五次会 议（以下简称"本次会议"）通知已于 2025 年 9 月 22 日以电子邮件方式送达全 体董事。本次会议于 2025 年 9 月 29 日在公司会议室以现场与通讯相结合的方式 召开。本次会议应到董事 9 人，实到董事 9 人，公司监事和高级管理人员列席了 本次会议。本次会议的内容以及召集、召开的方式、程序均符合《公司法》和《公 司章程》的规定。本次会议由董事长杨涛先生主持。与会董事经过充分的讨论， 通过以下决议： 公司董事会同意聘任周伟先生为公司副总经理，任期自本次董事会审议通过 之日起至公司第六届董事会任期届满之日止。 具体内容详见公司同日在中国证监会指定的创业板信息披露网站巨潮资讯网 披露的《关于聘任高级管理人员的公告》（公告编号：2025-043）。 证券代码：300030 证券简称：阳普医疗 公告编号：2025-042 阳普医疗科技股份有限公司 表决结果： ...

关于聘任高级管理人员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 9 月 29 日，阳普医疗科技股份有限公司（以下简称"公司"）召开 了第六届董事会第十五次会议，审议通过了《关于聘任周伟为公司副总经理的议 案》，具体情况如下： 基于公司发展及实际工作需要，经公司控股股东珠海格力金融投资管理有限 公司推荐，代理总经理蒋广成先生提名、董事会提名委员会审核，董事会决定聘 任周伟先生担任公司副总经理，任期自第六届董事会第十五次会议通过之日起至 第六届董事会届满之日止。 周伟先生具备担任公司副总经理的履职能力和任职资格，符合《中华人民共 和国公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》等法律法规、规范性文件以及《公司章程》的规定。 证券代码：300030 证券简称：阳普医疗 公告编号：2025-043 周伟先生简历详见附件。 特此公告。 阳普医疗科技股份有限公司 附件： 周伟先生简历 周伟先生，1979 年 1 月出生，本科学历，无境外永久居留权。2000 年 7 月 至 2011 年 12 月在新华社工作 ...

Group 1 - The core point of the news is that Yangpu Medical's stock has experienced a decline of 5.03% on September 23, with a total market value of 2.279 billion yuan and a trading volume of 36.18 million yuan, indicating a continuous downward trend over three days with a cumulative drop of 5.02% [1] - Yangpu Medical, established on August 19, 1996, and listed on December 25, 2009, is based in Zhuhai, Guangdong Province. The company specializes in providing technical solutions, products, and services for clinical testing laboratories and clinical care [1] - The main revenue composition of Yangpu Medical includes: vacuum blood collection systems (66.48%), reagents (12.23%), software products and services (10.03%), testing services (5.10%), other products (3.23%), instruments (2.81%), and microbiological transport systems (0.12%) [1] Group 2 - From the perspective of major fund holdings, Penghua Fund has one fund heavily invested in Yangpu Medical. The Penghua Smart Investment Digital Economy Mixed A Fund (020086) reduced its holdings by 31,800 shares in the second quarter, now holding 21,100 shares, which accounts for 0.62% of the fund's net value [2] - The fund has incurred a floating loss of approximately 8,229 yuan today, with a total floating loss of 8,651 yuan during the three-day decline [2] - The Penghua Smart Investment Digital Economy Mixed A Fund (020086) was established on May 17, 2024, with a latest scale of 5.1349 million yuan. Year-to-date returns are 44.8%, ranking 1,390 out of 8,172 in its category, while the one-year return is 100.02%, ranking 638 out of 7,995 [2]

Group 1: Company Governance - The board of directors consists of 9 members, with 3 from Zhuhai Gree Jin控 and 3 from the original company. In case of a tie (3:3), decisions are made based on a majority vote of all directors [2] - Board resolutions require a majority approval from all directors as per the company's articles of association [2] Group 2: Investor Relations Activities - The company participated in the "2025 Guangdong District Investor Reception Day" on September 19, 2025, from 15:30 to 17:00, via the "Panorama Roadshow" website [1] - The event aimed to enhance interaction and communication with investors regarding the company's operational status and other investor concerns [1] Group 3: Information Disclosure - The company adheres strictly to relevant laws and regulations regarding information disclosure and has no undisclosed information that should have been revealed [3]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300030 证券简称：阳普医疗 公告编号：2025-041 阳普医疗科技股份有限公司 关于参加2025年广东辖区投资者网上集体接待日活动的公告 阳普医疗科技股份有限公司董事会 2025 年 9 月 17 日 为进一步加强与投资者的互动交流，阳普医疗科技股份有限公司（以下简称 "公司"）将参加由广东证监局、广东上市公司协会联合举办的"向新提质 价 值领航——2025 年广东辖区投资者集体接待日暨辖区上市公司中报业绩说明 会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2025 年 9 月 19 日（周 五）15:30-17:00。 届时公司高管将在线就 2025 年半年度业绩等投资者关心的问题，与投资者 进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 ...

Core Viewpoint - The announcement indicates that Yangpu Medical's wholly-owned subsidiary has received regulatory approval for changes in the production address of its disposable vacuum blood collection containers, which is expected to enhance the company's competitiveness in the medical device sector [1] Group 1: Regulatory Changes - The production address for the disposable vacuum blood collection containers has been changed from "No. 6, Yizhang Avenue East, Yizhang Economic Development Zone, Hunan Province" to "No. 6, Yizhang Avenue East, Yizhang Economic Development Zone, Hunan Province; No. 8, Industrial Avenue, Lixian Economic Development Zone (Contracted Production)" [1] - The change includes the addition of a contracted production enterprise, "Wenjian Ping'an Medical Technology (Hunan) Co., Ltd." with the unified social credit code "91430723565949803B" [1] Group 2: Impact on Company - The registration change and continuation are expected to ensure product compliance and sustainability, which will positively impact the company's future development [1] - The changes are likely to enhance the overall competitiveness of the company's medical device products [1]

证券代码：300030 证券简称：阳普医疗 公告编号：2025-040 阳普医疗科技股份有限公司 关于全资子公司收到医疗器械变更注册（备案）文件及 完成延续注册的公告 本公司及全体董事会成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 (二）医疗器械延续注册情况 | 产品名称 | 一次性使用真空采血容器 | | --- | --- | | 注册证编号 | 湘械注准 20202221770 | | 注册类别 | Ⅱ类 | | 有效期至 | 2030 年 12 月 17 日 | | 适用范围 | 无菌采血管与一次性使用静脉采血针、持针器配合使用，非灭菌采 | | | 血管仅与具有防逆流作用的一次性使用静脉采血针、持针器配合使 | | | 用，用于人体静脉血的收集、运输、存储。 | 二、对公司的影响及风险提示 湖南阳普本次医疗器械变更注册（备案），增加了一次性使用真空采血容器 生产地址（委托生产），有利于湖南阳普拓宽生产渠道。 本次变更及延续注册有助于保障产品的合规与可持续性，有利于增强公司医 疗器械产品的综合竞争力，对公司未来发展有积极影响。 一、情况概述 近日，阳普医疗科技股份有限公司 ...

Group 1 - The core viewpoint of the news is that Yangpu Medical has seen a stock price increase of 5.14%, reaching 8.18 yuan per share, with a total market capitalization of 2.529 billion yuan as of the report date [1] - Yangpu Medical specializes in providing technical solutions, products, and services for clinical testing laboratories and clinical care, with its main business revenue composition being 66.48% from vacuum blood collection systems, 12.23% from reagents, and 10.03% from software products and services [1] - The company is located in Zhuhai, Guangdong Province, and was established on August 19, 1996, with its listing date on December 25, 2009 [1] Group 2 - From the perspective of fund holdings, Penghua Fund has one fund heavily invested in Yangpu Medical, specifically the Penghua Smart Investment Digital Economy Mixed A fund, which reduced its holdings by 3,180 shares in the second quarter [2] - The fund currently holds 21,100 shares of Yangpu Medical, representing 0.62% of the fund's net value, ranking as the eighth largest holding [2] - The Penghua Smart Investment Digital Economy Mixed A fund has achieved a year-to-date return of 38.26% and a one-year return of 86.81%, ranking 1303 out of 8180 and 549 out of 7978 respectively [2]

Summary of Key Points Core Viewpoint - As of August 19, 2025, 663 companies have released their semi-annual reports, with 432 reporting a year-on-year increase in net profit, while 231 reported a decline. Additionally, 440 companies saw an increase in operating revenue, and 223 experienced a decrease. A total of 355 companies reported simultaneous growth in both net profit and operating revenue, while 146 companies saw declines in both metrics. Notably, 111 companies achieved a net profit growth rate exceeding 100%, with Zhimingda leading at an impressive 2147.93% increase [1]. Company Performance - Zhimingda (688636) reported earnings per share of 0.2284, with a net profit of 38.30 million and a year-on-year increase of 2147.93%. Its operating revenue reached 294.76 million, reflecting an 84.83% increase [1]. - Rongzhirixin (688768) achieved a net profit of 14.24 million, marking a 2063.42% increase, with operating revenue of 25.63 million, up 16.55% [1]. - Shijia Guangzi (688313) reported a net profit of 216.65 million, a 1712.00% increase, and operating revenue of 992.63 million, up 121.12% [1]. - Aorui De (600666) had a net profit of 6.14 million, a 1263.22% increase, with operating revenue of 21.94 million, up 10.12% [1]. - Huile B (900939) reported a net profit of 4.21 million, a 1222.72% increase, with operating revenue of 0.76 million, slightly down by 0.11% [1]. Revenue and Profit Trends - The overall trend indicates a significant number of companies are experiencing substantial growth in both net profit and operating revenue, with a notable concentration of high growth rates among specific firms [1][2]. - Companies like Nanjiguang (300940) and Hongjing Technology (301396) also reported impressive growth rates in net profit of 982.43% and 725.73%, respectively, indicating a robust performance across various sectors [1][2].